Bayer: first participants in AskBio trial
Recruitment therefore continues in the US for the REGENERATE-PD clinical trial of the investigational gene therapy AB-1005 for the treatment of moderate-stage Parkinson's disease.
Phase Ib data at 36 months demonstrated a favorable safety profile and continued positive trends in the clinical measures assessed of AB-1005 with no associated serious adverse events.
' 'The randomization of the first participants to REGENERATE-PD is good news for people with Parkinson's disease and the physicians who treat them,' said Dr Rajesh Pahwa, Director of the Parkinson's Disease and Movement Disorder Center, University of Kansas Medical Center, USA, and principal investigator of REGENERATE-PD.
' There is a significant need for neurorestorative therapies for Parkinson's disease, and seeing an important investigational gene therapy progress through a Phase II clinical trial gives hope to patients and the medical community alike. '
Copyright (c) 2025 CercleFinance.com. All rights reserved.
Go to the original article.
Contact us to request a correction